{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037982","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.725597+00:00","generated_at":"2026-06-12T08:34:02.211309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alector reports Q2 net income $1.4M, cash $630M; updates clinical trial timelines","bullets":["Q2 2023 revenue $56.2M (down 30% YoY); net income $0.02 EPS vs $0.12 EPS in Q2 2022.","Cash, equivalents & investments $630M, expected to fund operations through 2025.","Guidance updated: 2023 collaboration revenue $90-100M (up), R&D $210-220M (down), G&A $60-65M.","Invoke-2 Phase 2 (AL002) enrollment completion Q3 2023; data readout Q4 2024.","INFRONT-3 pivotal trial enrollment completion expected Q4 2023; primary analysis on ~90-100 symptomatic FTD-GRN participants."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037982","json":"https://secwatch.observer/filing/0000950170-23-037982.json","markdown":"https://secwatch.observer/filing/0000950170-23-037982.md","text":"https://secwatch.observer/filing/0000950170-23-037982.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/0000950170-23-037982-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/alec-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:34:02.211309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5930037bca1ebd7236e3ee7d658adbc666dc5ed","claim":"Alector, Inc. reported the quarter ended June 30, 2023 results: revenue $56.2 million.","evidence_excerpt":"quarter of 2023 covering AL002 compositions and methods of use. Second Quarter 2023 Financial Results Revenue. Collaboration revenue for the quarter ended June 30, 2023, was $56.2 million, compared to $79.9 million for the same period in 2022. The $23.6 million decrease was mainly due to $68.9 million of collaboration revenue recognized in the second quarter of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/0000950170-23-037982-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Revenue","value":"$56.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}